StockDuty ← Dashboard Nov 04, 2026 09:59 PM ET
SignalEarnings

Revolution Medicines posted $198M in Q3 revenue, but that reflects about five weeks of RASONQUE plus EAP patient transitions and initial channel stocking, which management flagged as finite early-laun

Revolution Medicines posted $198M in Q3 revenue, but that reflects about five weeks of RASONQUE plus EAP patient transitions and initial channel stocking, which management flagged as finite early-laun

RVMD
$172.29
-2.30%
Revolution Medicines posted $198M in Q3 revenue, but that reflects about five weeks of RASONQUE plus EAP patient transitions and initial channel stocking, which management flagged as finite early-laun
Revolution Medicines posted $198M in Q3 revenue, but that reflects about five weeks of RASONQUE plus EAP patient transitions and initial channel stocking, which management flagged as finite early-laun — impact context not separately stored; see What changed.
Sources